https://www.live-feeds.com/feed/eli-lilly-ceo-tells-cnbc-one-third-of-new-glp-1-pill-patients-are-taking-foundayo-as-drugmaker-ramps-up-productionContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/eli-lilly-ceo-tells-cnbc-one-third-of-new-glp-1-pill-patients-are-taking-foundayo-as-drugmaker-ramps-up-productionhttps://www.live-feeds.com/feed/eli-lilly-ceo-tells-cnbc-one-third-of-new-glp-1-pill-patients-are-taking-foundayo-as-drugmaker-ramps-up-production#u82751Thu, 24 Sep 2026 17:36:55 +0000One-third of new patients starting on oral GLP-1 weight-loss medications are taking Eli Lilly drug Foundayo, according to company Chief Executive Officer Dave Ricks. The strong market adoption comes as the drugmaker actively ramps up production to meet surging demand in the lucrative obesity and weight-loss treatment sector. Alongside the commercial performance of its pill, Eli Lilly announced broader portfolio strength, noting that 70 percent of 700,000 new seniors starting GLP-1 medications following Medicare coverage are using Lilly products. To support long-term manufacturing needs, the co